Strong tablets—small, largely spherical, and simple to swallow—are a tried and true drug formulation, and making them contributes to a lot of Catalent’s income. However shopper spending on dietary and nutraceutical merchandise is rising, and with it, demand for softer and even chewable formulations. Catalent needs to chunk off an enormous chunk of this… Continue reading Catalent sees $1B Bettera deal as a key to growth in nutrition and consumer health